AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8911108 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (CDE) - cyclophosphamide, doxorubicin, etoposide
Number of subjects: 143
Study 1651434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (one injection daily)
Number of subjects: 105
Study 1651434 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low molecular weight heparin + dihydroergotamine (one injection daily)
Number of subjects: 105
Study 1651434 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (3 applications of 5000 IU per day)
Number of subjects: 105
Study 1651434 — intervention group
Group type: COMPARATOR
Intervention: Control group (Low molecular weight heparin alone)
Number of subjects: 105
Study 1651434 — intervention group
Group type: COMPARATOR
Intervention: Control group (Combination treatment)
Number of subjects: 105
Study 1651434 — intervention group
Group type: COMPARATOR
Intervention: Control group (Unfractionated heparin)
Number of subjects: 105
Study 6854869 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed periodic reprints (group 1)
Number of subjects: 132
Study 6854869 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly patient management problems (group 2)
Number of subjects: 132
Study 6854869 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study 6854869 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 132
Study 31883516 — intervention group
Group type: EXPERIMENTAL
Intervention: uPOD+PT
Number of subjects: 95
Study 31883516 — intervention group
Group type: COMPARATOR
Intervention: uPOD
Number of subjects: 95
Study 29391292 — intervention group
Group type: EXPERIMENTAL
Intervention: Video tutorial group
Number of subjects: 0
Study 29391292 — intervention group
Group type: COMPARATOR
Intervention: Control group (slide show)
Number of subjects: 0
Study 29391292 — intervention group
Group type: EXPERIMENTAL
Intervention: Video tutorial group (second simulation session)
Number of subjects: 0
Study 29391292 — intervention group
Group type: EXPERIMENTAL
Intervention: Video tutorial group (first simulation session)
Number of subjects: 0
Study 26541888 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated ileal-release glutamine (6.0 g)
Number of subjects: 32
Study 26541888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23661494 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week preoperative neuromuscular supervised exercise programme delivered twice a week for 1 hour as adjunct treatment to standard arthroplasty procedure
Number of subjects: 165
Study 23661494 — intervention group
Group type: COMPARATOR
Intervention: Standard arthroplasty procedure alone
Number of subjects: 165
Study 21678172 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance to snacks at 20 cm (proximal condition)
Number of subjects: 131
Study 21678172 — intervention group
Group type: COMPARATOR
Intervention: Distance to snacks at 70 cm
Number of subjects: 131
Study 21678172 — intervention group
Group type: COMPARATOR
Intervention: Distance to snacks at 140 cm
Number of subjects: 131
Study 21678172 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report ratings of salience and effort in Study 2
Number of subjects: 131
Study 21110409 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage (HD) medical exercise therapy
Number of subjects: 61
Study 21110409 — intervention group
Group type: COMPARATOR
Intervention: Low-dosage (LD) exercise therapy
Number of subjects: 61
Study 17956016 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray 200 g twice-daily (b.i.d.)
Number of subjects: 340
Study 17956016 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray 200 g once-daily (q.d.)
Number of subjects: 340
Study 17956016 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg three times daily (t.i.d.)
Number of subjects: 340
Study 17956016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 15875135 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O administration during washout of sevoflurane
Number of subjects: 20
Study 15875135 — intervention group
Group type: COMPARATOR
Intervention: Control group (sevoflurane and N2O discontinued immediately after surgery)
Number of subjects: 20
Study 12584874 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch (NTP; n = 27)
Number of subjects: 189
Study 12584874 — intervention group
Group type: COMPARATOR
Intervention: Bupropion SR (B; n = 101)
Number of subjects: 189
Study 12584874 — intervention group
Group type: COMPARATOR
Intervention: Bupropion SR plus nicotine patch (B + NTP; n = 61)
Number of subjects: 189
Study 10921056 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (40 Gy) followed by surgery (R + S)
Number of subjects: 201
Study 10921056 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (S)
Number of subjects: 201
Study 7978436 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg triazolam orally (Group 1)
Number of subjects: 47
Study 7978436 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 micrograms oral clonidine (Group 2)
Number of subjects: 47
Study 7978436 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms oral clonidine (Group 3)
Number of subjects: 47
Study 7978436 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms oral clonidine (Group 4)
Number of subjects: 47
Study 3140861 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen supplemented by 1.5 x MAC of halothane
Number of subjects: 40
Study 3140861 — intervention group
Group type: COMPARATOR
Intervention: 50% nitrous oxide, and 0.5% halothane (group 1, controls)
Number of subjects: 40
Study 3140861 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen supplemented by 1.5 x MAC of enflurane
Number of subjects: 40
Study 3140861 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen supplemented by 1.5 x MAC of isoflurane
Number of subjects: 40
Study 4407085 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 132
Study 4407085 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dextran 70
Number of subjects: 132
Study 4407085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Subcutaneous heparin and Intravenous dextran 70)
Number of subjects: 132
Study 31449685 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant antiplatelet therapy (APT)
Number of subjects: 2361
Study 31449685 — intervention group
Group type: COMPARATOR
Intervention: No concomitant antiplatelet therapy (Control group)
Number of subjects: 2361
Study 28534153 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab monotherapy
Number of subjects: 122
Study 28534153 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus carboplatin
Number of subjects: 122
Study 28534153 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (Bevacizumab monotherapy and Bevacizumab plus carboplatin)
Number of subjects: 122
Study 26377550 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced pelvic floor exercise program (Pfilates and Hypopressives) for 26 weeks
Number of subjects: 88
Study 26377550 — intervention group
Group type: COMPARATOR
Intervention: Conventional pelvic floor exercises for 26 weeks
Number of subjects: 88
Study 26377550 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced pelvic floor exercise program (Pfilates and Hypopressives)
Number of subjects: 88
Study 26377550 — intervention group
Group type: COMPARATOR
Intervention: Conventional pelvic floor exercises
Number of subjects: 88
Study 23416308 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9620 (0.3, 1, 2, 4, 6, 8 or 12 mg)
Number of subjects: 75
Study 23416308 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9620 (8 or 12 mg)
Number of subjects: 75
Study 23416308 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9620 (≥ 2 mg)
Number of subjects: 75
Study 23416308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 21135022 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐874 200 mg every other week (EOW)
Number of subjects: 215
Study 21135022 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐874 200 mg every week (EW)
Number of subjects: 215
Study 21135022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 19440081 — intervention group
Group type: EXPERIMENTAL
Intervention: lamotrigine
Number of subjects: 0
Study 19440081 — intervention group
Group type: EXPERIMENTAL
Intervention: divalproex sodium
Number of subjects: 0
Study 19440081 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 17234425 — intervention group
Group type: EXPERIMENTAL
Intervention: Blake 24F drain
Number of subjects: 150
Study 17234425 — intervention group
Group type: EXPERIMENTAL
Intervention: Jostra 32F silastic drain
Number of subjects: 150
Study 17234425 — intervention group
Group type: EXPERIMENTAL
Intervention: Argyle 32F plastic drain
Number of subjects: 150
Study 17234425 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 150
Study 15329205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cpd 861
Number of subjects: 136
Study 15329205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 11347832 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarthritis group (49 knees)
Number of subjects: 32
Study 11347832 — intervention group
Group type: COMPARATOR
Intervention: Control group (13 knees)
Number of subjects: 32
Study 10950467 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 43
Study 10950467 — intervention group
Group type: COMPARATOR
Intervention: Phenelzine
Number of subjects: 43
Study 8515823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (EGb 761, Tebonin)
Number of subjects: 12
Study 8515823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3461725 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg + codeine 16 mg + caffeine 30 mg
Number of subjects: 99
Study 3461725 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 99
Study 3461725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 31886591 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention (two consultations with a pharmacist 1-2 and 3-5 weeks after filling the prescription)
Number of subjects: 1480
Study 31886591 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users in the intervention group
Number of subjects: 1480
Study 31886591 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 1480
Study 31886591 — intervention group
Group type: COMPARATOR
Intervention: New statin users in the general population
Number of subjects: 1480
Study 29437940 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard LTBI treatment plus two-way weekly text messaging
Number of subjects: 358
Study 29437940 — intervention group
Group type: COMPARATOR
Intervention: Standard LTBI treatment
Number of subjects: 358
Study 26446245 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system
Number of subjects: 0
Study 25567150 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 48
Study 25567150 — intervention group
Group type: COMPARATOR
Intervention: Olmetec
Number of subjects: 48
Study 21912072 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg/day for 6 months)
Number of subjects: 0
Study 21912072 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 19358717 — intervention group
Group type: EXPERIMENTAL
Intervention: Stents for percutaneous coronary interventions
Number of subjects: 132
Study 17449579 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins (folate 1 mg, vitamin B‐12 500 microg, vitamin B‐6 10 mg)
Number of subjects: 276
Study 17449579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 15200744 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Lavage (JL)
Number of subjects: 205
Study 15200744 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Lavage plus Corticoids (JLC)
Number of subjects: 205
Study 12370452 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of two or more gadolinium-enhancing lesions
Number of subjects: 190
Study 12370452 — intervention group
Group type: EXPERIMENTAL
Intervention: Barkhof criteria
Number of subjects: 190
Study 12370452 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CDMS/MRI outcomes
Number of subjects: 190
Study 8083788 — intervention group
Group type: COMPARATOR
Intervention: Saline group, irrigation with 2 cc of physiologic saline
Number of subjects: 7
Study 8083788 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline group, irrigation with 2 cc of aqueous tetracycline hydrochloride, 50 mg/ml (5%)
Number of subjects: 7
Study 8083788 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine group, irrigation with 2 cc 0.12% chlorhexidine
Number of subjects: 7
Study 8083788 — intervention group
Group type: COMPARATOR
Intervention: Control group, no irrigation
Number of subjects: 7
Study 2686071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (NF) administered regularly for 2 months
Number of subjects: 15
Study 2686071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (NF) withdrawal after 2 months of administration
Number of subjects: 15
Study 1097611 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisoprodol
Number of subjects: 60
Study 1097611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31430755 — intervention group
Group type: COMPARATOR
Intervention: CBT (Cognitive Behaviour Therapy)
Number of subjects: 255
Study 31430755 — intervention group
Group type: EXPERIMENTAL
Intervention: ENCERT (CBT complemented with emotion regulation training)
Number of subjects: 255
Study 31430755 — intervention group
Group type: EXPERIMENTAL
Intervention: ENCERT
Number of subjects: 255
Study 29197203 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed physical activity (45 minutes, four times per week for 12 weeks)
Number of subjects: 80
Study 29197203 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed physical activity
Number of subjects: 80
Study 29197203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy and exercise
Number of subjects: 80
Study 29197203 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prescribed physical activity)
Number of subjects: 80
Study 25885323 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-components school-based and family-involved scheme conducted for 9 months
Number of subjects: 70000
Study 25885323 — intervention group
Group type: COMPARATOR
Intervention: Usual health practice (Control)
Number of subjects: 70000
Study 24070130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebroventricular transplantation of human neural stem/progenitor cells (NS/PCs) and rehabilitation training
Number of subjects: 52
Study 24070130 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation only
Number of subjects: 52
Study 20045584 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN)
Number of subjects: 20
Study 20045584 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 19030784 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical embolectomy (MERCI)
Number of subjects: 149
Study 19030784 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical embolectomy (Multi MERCI)
Number of subjects: 149
Study 19030784 — intervention group
Group type: COMPARATOR
Intervention: Intraarterial thrombolysis (PROACT II control)
Number of subjects: 149
Study 16938144 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended cognitive behaviour therapy (CBT) with or without behaviour strategies
Number of subjects: 2794
Study 16938144 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief introductory CBT
Number of subjects: 2794
Study 16938144 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer programs
Number of subjects: 2794
Study 15340532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential antiviral group (thymosin alpha1 1.6 mg, subcutaneous injection, 2 times/week for 8 weeks; interferon 500 MU, muscle injection, every other day for 6 months; lamivudine 100 mg/day after HBeAg seroconversion or interferon withdrawal for more than 18 months)
Number of subjects: 74
Study 15340532 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (interferon and thymosin alpha1 simultaneously for 6 months)
Number of subjects: 74
Study 15340532 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine group (more than 18 months treatment with lamivudine)
Number of subjects: 74
Study 11589607 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined general anaesthesia and epidural analgesia
Number of subjects: 50
Study 11589607 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 50
Study 9598254 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg.kg‐1 mivacurium
Number of subjects: 180
Study 9598254 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide-opioid anaesthesia
Number of subjects: 180
Study 9598254 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide-halothane anaesthesia
Number of subjects: 180
Study 7834990 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II infusion at 10 ng min‐1 kg‐1
Number of subjects: 10
Study 7834990 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II infusion at 2 ng min‐1 kg‐1
Number of subjects: 10
Study 7834990 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II infusion at 5 ng min‐1 kg‐1
Number of subjects: 10
Study 7834990 — intervention group
Group type: COMPARATOR
Intervention: D‐aldosterone infusion
Number of subjects: 10
Study 7834990 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% NaCl)
Number of subjects: 10
Study 3165298 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (IFN alpha-2b) administered three times a week at doses of 2 or 5 X 10(6) IU/m2 for chronic phase patients; 5 X 10(6) IU/m2 for accelerated phase patients.
Number of subjects: 82
Study 3165298 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of Interferon alpha-2b (IFN alpha-2b) at doses from 2 to 5 X 10(6) IU/m2.
Number of subjects: 82
Study 3165298 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (IFN alpha-2b) for more than 3 months.
Number of subjects: 82
Study 3165298 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (IFN alpha-2b) in chronic phase patients.
Number of subjects: 82
Study 3165298 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (IFN alpha-2b) treatment.
Number of subjects: 82
Study 29691840 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular screening
Number of subjects: 50156
Study 29691840 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no screening)
Number of subjects: 50156
Study 25689546 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella 2.5 (IR2.5)
Number of subjects: 325
Study 23485864 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone supplementation
Number of subjects: 26
Study 23485864 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 26
Study 23485864 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH pulses/saline
Number of subjects: 26
Study 23485864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GHRH pulses/GHRP-2
Number of subjects: 26
Study 23485864 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline pulses/GHRP-2 drive
Number of subjects: 26
Study 23485864 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline/GHRP-2 infusion
Number of subjects: 26
Study 23485864 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple stimulus preceded by GHRH/GHRP-2
Number of subjects: 26
Study 23485864 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2
Number of subjects: 26
Study 21428766 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 602
Study 21428766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 18061658 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular mail
Number of subjects: 94
Study 18061658 — intervention group
Group type: COMPARATOR
Intervention: Choice of regular mail, computer telephony, or e-mail
Number of subjects: 94
Study 18061658 — intervention group
Group type: COMPARATOR
Intervention: Computer telephony
Number of subjects: 94
Study 18061658 — intervention group
Group type: COMPARATOR
Intervention: Regular mail vs. computer telephony
Number of subjects: 94
Study 16435002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheddar cheese added to baked potato
Number of subjects: 40
Study 16435002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheddar cheese added to pasta
Number of subjects: 40
Study 16435002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheddar cheese added to toast
Number of subjects: 40
Study 16435002 — intervention group
Group type: EXPERIMENTAL
Intervention: Various toppings (including chilli con carne, baked beans, and tuna) added to baked potato
Number of subjects: 40
Study 16435002 — intervention group
Group type: EXPERIMENTAL
Intervention: Various toppings (including chilli con carne, baked beans, and tuna) added to pasta
Number of subjects: 40
Study 16435002 — intervention group
Group type: EXPERIMENTAL
Intervention: Various toppings (including chilli con carne, baked beans, and tuna) added to toast
Number of subjects: 40
Study 12946084 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency rTMS (15 Hz)
Number of subjects: 18
Study 12946084 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency rTMS (1 Hz)
Number of subjects: 18
Study 12946084 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study 10839492 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy, concomitant chemotherapy, or radiotherapy alone
Number of subjects: 0
Study 10839492 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study 9324434 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nutritional support
Number of subjects: 28
Study 9324434 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative nutritional support
Number of subjects: 28
Study 9324434 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 28